



For Immediate Release

Media Contact

Chris Gale
(646) 695-2883
cgale@greentarget.com

WPS Now Covering AmnioX Medical Products

NEOX® Wound Allograft Accessible to More than 4.4 Million Additional Medicare Lives

ATLANTA, GA – March 30, 2016—AMNIOX Medical, Inc., a TissueTech, Inc. company, announced Wisconsin Physicians Service Insurance Corp. (WPS) will provide Medicare coverage for its NEOX® Wound Matrix, including the first umbilical cord allograft available to clinicians to treat chronic, non-healing wounds.

As the Medicare Administrative Contractor (MAC) for Jurisdiction 5 and Jurisdiction 8, WPS currently administers both Part A and Part B Medicare benefits for Iowa, Kansas, Missouri, Nebraska, Indiana and Michigan, covering 4.4 million lives. WPS also administers certain national provider Medicare programs for 40 states.

Medicare covers the majority of patients with chronic wounds that are appropriate for treatment with the unique umbilical cord product from AmnioX. Novitas Solutions, Noridian Healthcare Solutions, and First Coast Services Options have also implemented similar positive reimbursement policies related to the use of umbilical cord and amniotic membrane products to promote wound healing. Together with WPS they cover 24 million lives, or more than 60 percent of lives covered by Medicare nationwide.

AmnioX parent TissueTech pioneered the clinical application of human umbilical cord and amniotic membrane to promote rapid, scarless healing that occurs in utero to wounds in adults. Since the company's inception, clinicians have performed more than 200,000 human transplants of its products and published more than 300 peer-reviewed studies supporting its technology platform. AmnioX Medical was formed in 2011 to focus on the orthopedic and wound care markets.

"The continued expansion of Medicare coverage illustrates a developing understanding among payers of the clear benefits that our unique products offer, and follows the ongoing adoption among providers," said Thomas J. Dugan, CEO of AmnioX. "AmnioX is committed to developing further access, as well as the clinical evidence that underpins adoption."

In utero, wound healing occurs rapidly and with minimal scar. This restorative ability is innate to placental tissues, including umbilical cord and amniotic membrane. Heavy chain hyaluronic acid/pentraxin-3 is the key protein complex present in these tissues to orchestrate the healing process. AmnioX Medical is the first provider of a human tissue allograft composed of both umbilical cord and amniotic membrane. AmnioX utilizes its proprietary CryoTek® process, a cryopreservation technology, to preserve the biological

and structural integrity of the native tissue and published studies have demonstrated that the CryoTek process more effectively preserves the structural and biological integrity of the tissue.

About Amniox Medical, Inc.

Founded in 2011 to serve the orthopedic and wound care markets, Amniox Medical is dedicated to developing and marketing regenerative therapies processed from umbilical cord and amniotic membrane utilizing its proprietary CryoTek technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. Amniox Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products. For additional information, please visit <http://www.amnioxmedical.com>.

About TissueTech, Inc.

TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; BioTissue develops and markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) has supported TissueTech's research with more than 25 continuous years of research grants. Since the company's inception, clinicians have performed more than 200,000 human implants of the company's products and published more than 300 peer-reviewed studies supporting its technology platform. The Company's first product, AmnioGraft[®], is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.

###